Mersana Therapeutics (MRSN) Investment Analysis– Opportunities and Risks from an ADC Platform & Day One Acquisition Deal Perspective
Mersana Therapeutics (MRSN) Investment Analysis – Opportunities and Risks from an ADC Platform & Day One Acquisition Deal Perspective※ Mersana Therapeutics (NASDAQ: MRSN) is a clinical-stage biotech focused on antibody–drug conjugates (ADCs). It develops next-generation ADC pipelines for solid tumors using its cytotoxic platform Dolasynthen and STING-agonist platform Immunosynthen. Key assets in..
TIPs/주식
2025. 11. 13. 20:57